Feature Channels: Pharmaceuticals

• share
• favorite_border

Researchers from Cornell University have identified a possible target for antiviral treatment for COVID-19.

• share
• favorite_border

A team of Stony Brook University (SBU) researchers is working on computer models that could help speed the discovery of drugs to combat the novel coronavirus responsible for COVID-19. They are doing this work in collaboration with scientists at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory and Argonne National Laboratory, and will be leveraging those laboratories’ computational resources and expertise.

• share
• favorite_border

Today, the American Thoracic Society announced that Boehringer Ingelheim Pharmaceuticals, Inc., donated $500,000 to support the ATS COVID-19 Crisis Fund, a newly launched initiative to develop and disseminate research, education and scientific recommendations to providers in the pulmonary and critical care communities, as well as other clinicians in need of expanding their skill set during this emergency. Boehringer Ingelheim is the first to make a donation to the Fund.

• share
• favorite_border

A team of physician-scientists at Beth Israel Deaconess Medical Center are now enrolling patients in a clinical trial to evaluate a common anti-clotting drug for the treatment of COVID-19-positive patients with ARDS. The newly launched trial follows a special report the team published in the Journal of Trauma and Acute Care Surgery that suggested the use of a drug called tPA could reduce deaths among patients with ARDS as a complication of COVID-19.

• share
• favorite_border

Rush University Medical Center is participating in a new clinical trial to test the effectiveness of the drug remdesivir in the treatment of coronavirus disease 2019 (COVID-19).

• share
• favorite_border

A new trial led by the Perelman School of Medicine at the University of Pennsylvania will evaluate whether the drug hydroxychloroquine (HCQ) can benefit people infected with COVID-19, as well as whether taking the drug preventatively may help people avoid infection altogether

• share
• favorite_border

UCLA Health is one of 75 sites around the globe participating in a clinical trial sponsored by the National Institutes of Health to test the effectiveness of a candidate anti-viral drug against COVID-19.

• share
• favorite_border

An international team led by University of British Columbia researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts.

• share
• favorite_border

Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center, is offering a clinical trial as a potential treatment for patients diagnosed with the coronavirus (COVID-19). The trial, which is not limited to cancer patients is exploring hydroxychloroquine and azithromycin.

• share
• favorite_border

Montefiore Health System and Albert Einstein College of Medicine has joined a clinical trial to evaluate the experimental drug remdesivir to treat people who are hospitalized with severe COVID-19 infection.

• share
• favorite_border

• share
• favorite_border

Announcement from the Harrington Discovery Institute at University Hospitals of a new initiative that galvanizes its transatlantic network of academic institutions, foundations, and philanthropic partners to accelerate promising, near-term therapies to treat COVID-19 and its complications and battle future pandemic threats. In advancing its portfolio of 120 drugs-in-the-making at 54 leading academic centers in North America and the U.K., HDI has developed a proven model that has enabled scientists in academia to accelerate their breakthrough drug discoveries toward trials in patients.

• share
• favorite_border

Media are invited to attend and ask questions at this Virtual Press Conference with a Newswise Live Expert Panel to discuss the COVID-19 crisis.

• share
• favorite_border

A potential COVID-19 vaccine, delivered by microscopic needles, produces antibodies specific to the virus when tested in mice. This is the first peer-reviewed paper describing a COVID-19 vaccine candidate. The next step is a human clinical trial.

• share
• favorite_border

University Hospitals announced it will lead a clinical trial that involves the administration of an investigational drug, ARMS-I, to its caregivers working on the frontlines of the COVID-19 pandemic. The trial, named the ARMS-I COVID Study, is designed to assess whether the drug helps prevent airborne transmission of coronavirus and whether it reduces the symptoms of healthcare providers who have tested positive for the virus.

• share
• favorite_border

The University of Illinois at Chicago is participating in two clinical trials for COVID-19 treatments.

• share
• favorite_border

Houston Methodist nanomedicine researchers are studying a new drug delivery system that transports oral medication via triglycerides that could eliminate the need for injections or IV treatments of some biologic drugs for rheumatoid arthritis and other autoimmune diseases. They’re doing this with a diabetes drug that resulted in approximately 25% absorption in mice models, considered very high for an oral drug. The research will appear in Science Advances April 1.

• share
• favorite_border

Cedars-Sinai has joined an international effort to test an experimental antiviral drug as a potential treatment for COVID-19 (coronavirus). The institution expects to enroll its first clinical trial participant this week.

• share
• favorite_border

Individuals taking a class of steroid hormones called glucocorticoids for conditions such as asthma, allergies and arthritis on a routine basis may be unable to mount a normal stress response and are at high risk if they are infected with the virus causing COVID-19, according to a new editorial published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.

• share
• favorite_border

Teprotumumab, the first FDA-approved medicine for thyroid eye disease, provides significant improvement in eye bulging, regardless of patient gender, age or smoking status, according to a study accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.